Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.For the commercial launch of MuGard
Subscribe to our email newsletter
Imedicor has signed an agreement with Dallas-based Access Pharmaceuticals for the North American commercial launch of MuGard, its FDA-approved oral wound rinse for the management of oral mucositis and stomatitis caused by radiotherapy and/or chemotherapy.
MuGard is used prophylactically for patients undergoing chemotherapy and radiation therapy for the management of oral mucositis, a painful inflammation of the mouth’s mucous membranes. This side affect afflicts approximately 80% of cancer patients receiving radiation therapy and 40% of cancer patients receiving chemotherapy.
The company said that in return to its online marketing services, iMedicor will receive a monthly fee, click-through revenue and a royalty of up to 5% of all product sales generated through iMedicor’s portal.
Jeffrey Davis, president and chief executive at Access, said: “iMedicor’s powerful web portal presents us with an invaluable and low-cost option to reach the exact physician demographic we seek in our marketing efforts. We look forward to working with iMedicor to deliver information on MuGard™ to the over 200,000 specialty practices in the U.S. that treat cancer patients with this painful radiation and chemotherapy side effect.”
Fred Zolla, chief executive at iMedicor, said: “We are very pleased to be aligned with Access Pharmaceuticals in this effort. By placing targeted messages into the hands of specific physicians and their staff at the point of care, we are confident that Access will achieve far greater ROIs on their marketing efforts.”
Access Pharmaceuticals is a biopharmaceutical company that develops and commercializes products for the treatment and supportive care of cancer patients. In addition to MuGard, Access’ products include ProLindac, currently in phase 2 clinical testing of patients with ovarian cancer and also under study for its potential role in combination with other pharmaceuticals in the treatment of hepatocellular carcinoma (a form of liver cancer), and pancreatic cancer.